Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
The American Medical Association and University of Minnesota's Vaccine Integrity Project are creating an independent vaccine review system after major changes at the CDC raised concerns among public health experts.
Ten63 Therapeutics announced strategic investment from Chugai Venture Fund and the Gates Foundation, bringing total funding to more than $45 million to advance its BEYOND AI drug discovery platform targeting previously undruggable proteins.
The U.S. FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as monotherapy for adults with advanced head and neck squamous cell carcinoma, based on Phase 1b/2 study data showing rapid and durable responses.
The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Multiple law firms have filed securities class actions against Inovio Pharmaceuticals after the FDA accepted its INO-3107 BLA for standard rather than accelerated review, following earlier manufacturing delays with the CELLECTRA device.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07562984 |
A Bio-Psycho-Social Medical Model-Based Study on Adolescent Female HPV Vaccination Behavior and Comprehensive Intervention |
NOT_YET_RECRUITING | NA |
| NCT07498075 |
Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers |
NOT_YET_RECRUITING | NA |
| NCT07493928 |
HPV After chemoRadioTherapy |
RECRUITING | |
| NCT07468695 |
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS2 Kenya |
NOT_YET_RECRUITING | NA |
| NCT07438080 |
Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study |
RECRUITING | NA |
| NCT07390916 |
Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda |
NOT_YET_RECRUITING | NA |
| NCT07376031 |
Cervical Thermal Ablation to Treat Persistent HPV Infection |
COMPLETED | NA |
| NCT07345897 |
Emergency Department-based Cervical Cancer Screening Through Self-sampling |
RECRUITING | NA |
| NCT07336134 |
PopSci CHW4CervixHealth |
RECRUITING | NA |
| NCT07303751 |
Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV |
NOT_YET_RECRUITING | PHASE2 |
